Screening Tools May Miss Key Aspects of Patient Financial Toxicity
A comparative study shows standard screening measures may not fully capture financial strain and worry in cancer patients.
Key takeaways
- A comparative study shows that a single screening tool may fail to capture the full spectrum of financial toxicity for cancer patients.
- Patient accounts of financial toxicity are comprised of two distinct elements: financial strain and financial worry.
- For 14 out of 20 interviewed patients, standard screening scores from COST-FACIT or ENRICh did not fully reflect their qualitative accounts of strain and worry.
- Researchers suggest a stepwise, wholistic screening approach using more than one measure may better connect patients to financial resources.
Patients with cancer who are prescribed targeted oral anticancer medications (TOAMs) navigate financial challenges. To identify those experiencing financial toxicity, clinical centers use standardized screening tools, but the best approach to identify patients for targeted interventions remains unclear. A study published in the Journal of Cancer Survivorship: Research and Practice in September 2026 compared how patients describe their financial challenges in interviews with their scores on two screening instruments.
The research team compared qualitative accounts of financial toxicity among patients receiving TOAMs to their scores on the COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) and the Economic Strain and Resilience in Cancer (ENRICh) screening tools. The findings suggest that relying on a single measure may leave some patient experiences uncaptured, as individual screening tools did not fully reflect both the practical strain and emotional worry of every participant.
What Happened
The investigators conducted a mixed-methods analysis of adult patients at a comprehensive cancer center. Eligible participants had a confirmed cancer diagnosis and orders for TOAMs within the prior three months. A total of 108 patients completed surveys. From this group, a subset of 20 patients whose COST-FACIT scores indicated financial toxicity participated in semi-structured interviews. The researchers applied the Framework Method to analyze these qualitative accounts and developed joint matrices to assess how well each screening tool identified financial toxicity.
What The Evidence Shows
The qualitative interviews highlighted two key elements of financial toxicity: financial strain and financial worry. For a subset of six participants who had extreme accounts of both financial strain and financial worry, both the COST-FACIT and the ENRICh scores indicated medium to high levels of financial toxicity. However, for the remaining 14 participants, their qualitative accounts of financial strain and financial worry were not completely captured by the COST-FACIT, the ENRICh tool, or both.
What We Don't Know Yet
The published source does not report the overall study stage, sample size beyond the 108 survey and 20 interview participants, or specific patient demographic and clinical characteristics. Additionally, the study was conducted at a single comprehensive cancer center, which may limit the direct generalizability of the findings to other healthcare settings.
What Comes Next
The published study does not report specific plans for future research, clinical trials, or next steps by the investigators or sponsors. The findings leave open the question of how healthcare institutions can best design and implement a multi-measure, stepwise screening protocol to accurately identify financial toxicity and route patients to targeted supportive interventions.
What This Means
These findings suggest that a single screening measure may not adequately identify financial toxicity or differentiate between the distinct experiences of financial strain and financial worry. The researchers conclude that a stepwise, wholistic approach may be more effective to identify patients and connect them to appropriate resources.
Original Source
PubMed (NCBI E-utilities): https://pubmed.ncbi.nlm.nih.gov/42697984/
Questions readers ask
- What is financial toxicity in cancer care?
- Financial toxicity refers to the financial strain and emotional worry patients experience due to the costs of cancer treatment, such as targeted oral anticancer medications.
- What screening tools did this study evaluate?
- The study compared the COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) and the Economic Strain and Resilience in Cancer (ENRICh) tools.
- Why might a single screening tool be insufficient?
- The study found that for 14 out of 20 interviewed patients, standard screening tools did not fully capture both the practical financial strain and emotional worry they experienced.
What this means
These findings suggest that a single screening measure may not adequately identify financial toxicity or differentiate between the distinct experiences of financial strain and financial worry. The researchers conclude that a stepwise, wholistic approach may be more effective to identify patients and connect them to appropriate resources.
Limitations and uncertainties
- The published source does not report the overall study stage, sample size beyond the 108 survey and 20 interview participants, or specific patient demographic and clinical characteristics. Additionally, the study was conducted at a single comprehensive cancer center, which may limit the direct generalizability of the findings to other healthcare settings.
